SecBot SecBot
SECBOTREPLAY Home › Report › ABBV

ABBV · The District of North Dakota denied North Dakota's motion to stay a…

AbbVie Inc. · COURT-RULING filed Jul 26, 2026 at 20:00 ET

At the news

BULLISHIMPACT 6/10

COURT-RULING filed Jul 26, 2026 at 20:00 ET

The District of North Dakota denied North Dakota's motion to stay a permanent injunction pending appeal, keeping AbbVie's win intact. The injunction blocks enforcement of a state law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program, with AbbVie estimating the law cost it $10M in 2025 and would cost another $35M in 2026 in discounted sales. The denial removes near-term uncertainty and preserves AbbVie's ability to operate under the federal program without state-imposed penalties, a material positive for its 340B revenue stream.

  • Court denied North Dakota's motion to stay a permanent injunction pending appeal.
  • The permanent injunction blocks enforcement of a North Dakota law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program.
  • AbbVie estimated the law cost it $10 million in 2025 and will cost another $35 million in 2026 in discounted sales it would not make but for the law.
  • The court found North Dakota unlikely to succeed on the merits, citing the law's criminal penalties and direct price regulation as key differences from other state laws.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access